The reliance on insulin-based therapy in dogs and cats with diabetes reflects biological factors, such as species-specific pharmacokinetics, and regulatory limitations, as few antidiabetic agents received formal approval for veterinary use [133,134]. This evidence concerns the gene INS and diabetes mellitus.